As the administration of President Donald Trump intensifies its campaign to go ahead and align the US drug prices with global levels, AstraZeneca has gone on to become the latest pharmaceutical giant to sign on. The agreement, which was unveiled at a White House ceremony, happens to commit the company to offering discounts when it comes to prescription medicines and also major new investment within US manufacturing.
As per the deal, AstraZeneca is going to introduce Direct-to-Consumer (DTC) pricing for eligible patients. AstraZeneca will offer almost 80% off on list prices of U.S. drugs. The company is also going to participate in the TrumpRx platform, which enables the patients to purchase medicines directly at decreased cash prices.
The Chief Executive Officer of AstraZeneca, Pascal Soriot, said that the initiative is going to make the life-changing medicines much more accessible, adding that it would also help to safeguard the pioneering role of America as a global powerhouse when it comes to innovation.
$50bn US investment along with tariff relief
As AstraZeneca will offer almost 80% off, in exchange, the US Department of Commerce is going to delay the proposed tariffs on pharmaceutical imports from AstraZeneca for three years. This is going to give the company time to onshore production and simultaneously expand its research presence. Apparently, AstraZeneca has already pledged to invest $50bn in the next five years in US facilities, thereby targeting $80bn in total revenue by the end of the decade, half of which it anticipates to generate domestically.
The most-favored-nation pricing plan of Trump
The deal happens to form part of the most-favored-nation pricing strategy from Trump that was first announced in May 2025, which looks forward to pegging US drug prices to those across other wealthy countries. According to Trump, for many years, Americans have gone on to pay the highest prices in the world when it comes to prescription drugs, by far. A RAND study went on to find out that US drug prices happened to be 2.78 times higher on average as compared to those across 33 comparable nations, highlighting the scale of the issue the plan looks forward to addressing.
Industry response along with future outlook
It is well to be noted that Pfizer happened to be the first to join the initiative by Trump, offering discounts of almost 85% by way of TrumpRx, while Amgen recently went ahead and launched AmgenNow, offering 60% off on evolocumab, its cholesterol drug. The coming months are going to reveal whether there will be more companies that follow their lead and whether the lower prices when it comes to patients can be sustained without causing any effect on the R&D investment.